Sushma Kaul, MD
Pulmonary Disease · Utica, NYNPI 1952317091
Payments from drug & device makers
Across 306 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Sanofi$413
- Boehringer Ingelheim$404
- Regeneron Healthcare Solutions, Inc.$305
- Actelion Pharmaceuticals US, Inc.$251
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,87197%
- Education$1773%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 95 | $1,609 |
| GSK | 80 | $1,268 |
| Sanofi | 17 | $413 |
| Boehringer Ingelheim | 20 | $404 |
| Regeneron Healthcare Solutions, Inc. | 14 | $305 |
| Actelion Pharmaceuticals US, Inc. | 6 | $251 |
| United Therapeutics Corporation | 5 | $210 |
| Novartis | 8 | $192 |
| Electromed, Inc. | 9 | $183 |
| Philips North America LLC | 7 | $151 |
| Boston Scientific | 2 | $145 |
| Phathom Pharmaceuticals, Inc. | 1 | $105 |
| Amgen | 4 | $86 |
| Paratek Pharmaceuticals, Inc. | 4 | $82 |
| Insmed, Inc. | 5 | $77 |
| Teva Pharmaceuticals USA, Inc. | 5 | $77 |
| Verona Pharma, Inc. | 3 | $69 |
| Pfizer | 4 | $68 |
| Mylan Specialty L.p. | 3 | $50 |
| Shionogi Inc | 2 | $39 |
| Pulmonx Corporation | 1 | $39 |
| Mallinckrodt Enterprises LLC | 1 | $34 |
| Astellas Pharma US Inc | 1 | $30 |
| Ambu Inc. | 1 | $25 |
| Inogen, Inc. | 1 | $25 |
| Grifols USA, LLC | 1 | $21 |
| Abiomed | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Mallinckrodt Hospital Products Inc. | 1 | $12 |
| Circassia Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,048 in reported general payments places this provider in the 70th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 46 | $604,117 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 301 | $282,339 |
| Dupixent PenDupilumab | 33 | $153,264 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 100 | $114,041 |
| Breo ElliptaFluticasone/Vilanterol | 146 | $100,260 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 83 | $62,669 |
| Spiriva RespimatTiotropium Bromide | 30 | $32,881 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $13,582 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $13,117 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 21 | $12,394 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $11,992 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 32 | $11,930 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 256 | $11,172 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $10,911 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 47 | $10,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $404 | $663,697112 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,268 | $445,268530 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort, Daliresp | $1,609 | $148,280177 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $77 | $4,21815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Utica
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.